The purpose of this study is to evaluate the performance of DAILIES TOTAL1® and ACUVUE OASYS® 1-DAY and with respect to visual acuity in a symptomatic study population of monthly or bi-weekly replacement lens wearers.

Inclusion Criteria:

• Able to understand and must sign an IRB-approved informed consent form;
• Soft contact lens wearers in both eyes during the past 3 months;
• Best-corrected visual acuity (BCVA) 20/25 or better in each eye;
• Willing to wear study lenses at least 3 days per week and at least 8 hours per day;
• Willing to stop wearing habitual contact lenses for the duration of study participation.

Exclusion Criteria:

• Infection, inflammation, abnormality, condition, disease, surgery, or use of medications, as specified in the protocol;
• Intolerance, hypersensitivity, or allergy to any component of the study products;
• Wearing habitual contact lenses in an extended wear modality (routinely sleeping in lenses for at least 1 night per week) over the last 3 months prior to enrollment;
• Monocular (only one eye with functional vision).

This analysis population includes all subjects/eyes exposed to any test or control product evaluated in the study (Safety Analysis Set).

Dispense through study completion, an average of 4 weeks

An Adverse Event (AE) was defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs in subjects, users, or other persons, whether or not related to the study lenses. AEs were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. Safety Analysis Set. "At Risk" population for ocular AEs is included with unit of "eyes."